Evidence map›Paper›PMID 42755849›Full record

ArticleFrontiers in public health2026

Traditional Chinese medicine reimbursement reform in China: implementation progress, policy constraints, and optimization strategies.

Fazheng Zhao, Yichi Chen, Xin Tong

Abstract read
In one paragraph

Article in Frontiers in public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Fazheng Zhao *Zhejiang Cultural Research Institute of Chinese Medicine, Zhejiang Chinese Medical University, Hangzhou, China.
Yichi Chen *College of Humanities and Management, Zhejiang Chinese Medical University, Hangzhou, China.
Xin TongCollege of Humanities and Management, Zhejiang Chinese Medical University, Hangzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: As the inheritance, innovation, and development of TCM advance, medical insurance reimbursement policies are intended to improve access, guide service structure, and support high-quality development. This study examines the implementation progress, policy constraints, and optimization paths of TCM reimbursement reform in China. Methods: The study analyzes publicly available national and regional policy documents, together with secondary literature, to synthesize the policy design, implementation arrangements, and evidence boundaries of TCM reimbursement reform. Results: The policy corpus suggests that national and local governments have progressively expanded insurance support for eligible TCM institutions, techniques, and decocted herbal medicines, creating institutional conditions for broader reimbursement arrangements. At the implementation level, some regions have explored TCM outpatient syndrome-differentiation fees, DRG-based incentives, and outpatient global-budget management. However, current payment rules still do not fully align with TCM diagnostic and treatment characteristics. Key issues include incomplete recognition of syndrome differentiation and treatment value under DRG payment, low TCM service prices, insufficient reimbursement levels, static control of TCM decoction pieces costs, tension between zero-markup policies and payment reform, and immature quality-evaluation mechanisms under centralized procurement. Conclusion: Based on these findings, the study proposes refining TCM-specific payment and pricing mechanisms, adjusting disease grouping and payment rules, dynamically revising cost-control standards, coordinating markup reform with compensation policies, and developing quality grading and "higher quality, higher price" mechanisms for herbal materials. Because the evidence is primarily policy-level, the study identifies policy instruments and implementation pathways rather than causal effects on service utilization, patient access, fund expenditure, or clinical outcomes.

Indexed as

Health Care ReformHealth PolicyInsurance, Health, ReimbursementMedicine, Chinese TraditionalReimbursement MechanismsChinaHumansDRG paymenthealth insurance payment reformreimbursement policytraditional Chinese medicinevalue-based payment

Identifiers

PMID42755849
PMCPMC13581920

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.